Document is current

Article History

Accepted: 16 April 2025

First Online: 11 May 2025

Declarations

:

: Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. The medical writing assistance was supported by UCB España, who did not influence any aspect of the study design, data collection, analysis or interpretation, or the decision to submit the manuscript for publication.

: R.Q. has received payment for scientific consultancy, research projects, conferences, attendance at meetings and congresses, and training activities, from Abbvie, Amgen, Eli-Lilly, Johnson & Johnson, MSD, Novartis, Pfizer and UCB. He has also received unrestricted grants for research from Abbvie, Novartis, Johnson & Johnson and UCB. J.P.T. has received consulting and advisory board fees and research grants from Bristol Myers Squibb, Celgene, AbbVie, BMS, Janssen, Novartis, Pfizer and UCB. C.M.M. has received payment for training activities from Amgen.

: R.Q. is responsible for the conceptualisation and design of the review, critically reviewing and revising all drafts of the review, and approving the final version of the manuscript. J.A.P.T. and C.M.M. critically reviewed and revised all drafts of the manuscript and approved the final version.

: Data availability is not applicable to this article as no new data were generated or analysed in this narrative review.

: Not applicable as the manuscript does not include identifiable human data.

: Not applicable as the manuscript does not include identifiable human data.

: Not applicable.

: Not applicable to this review article.